Skip to main content

Table 5 Mitoxantrone and anthracycline trials: survival outcomes.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial Treatment arms Overall survival Progression-free survival or TTP
   N Median (mo) Statistical comparison N Median (mo) Statistical comparison
Berry, 2002 [69] mitoxantrone prednisone 56 23 p = 0.48 56 8.1 p = 0.018 (TTP)
  prednisone 63 19   63 4.1  
Kantoff, 1999 [70] mitoxantrone 119 12.3 p = 0.77 119 3.7 p = 0.02 (TTP)
  hydrocortisone 123 12.6   123 2.3  
Tannock, 1996 [71] mitoxantrone prednisone 80 NR p = 0.27 NR
  prednisone 81      
Weissbach, 1998 [88] epirubicin 61 NR by treatment group   61 NR by treatment group "TTF was longer with mitomycin C vs. EMP (p = 0.037); and vs. epirubicin (p = 0.039)
  EMP 54    54   
  mitomycin C 60    60   
Anderström, 1995 [72] epiribucin MPA 73 11.5 p = NS 73 7.6 p = 0.013 (TTP)
  EMP 72 9.5   72 4.3  
Laurie, 1992 [73] 5-FU doxorubicin mitomycin C (combined) 70 8.7 p = 0.025 NR
  5-FU doxorubicin mitomycin C (sequential) 72 7.1     
Saxman, 1992 [74] cyclophosphamide doxorubicin methotrexate 26 high PS 24 low PS 9.5 6 p = 0.93 p = 0.51 p = 0.7 (unstratified) 50 6.2* p = 0.07 (TTP)
  cyclophosphamide 26 high PS 27 low PS 9 5   53 4.4*  
Murphy, 1988 [75] doxorubicin cyclophosphamide 54 NR p = NS 54 NR p = NS
  cisplatin 5-FU cyclophosphamide 46    46   
  methotrexate 52    52   
Stephens, 1984 [76] doxorubicin cyclophosphamide 68 6.8 p = NS NR
  hydroxyurea 69 7     
  1. *Median values include only patients with partial response or stable disease (n was not reported).
  2. Abbreviations: 5-FU – 5- fluorouracil; EMP – estramustine phosphate; mo – months; MPA – medroxyprogesterone; N – number; NR – not reported; NS – non-significant; PS – performance status; TTF – time-to-treatment failure; TTP – time-to-progression; vs – versus.